Childhood tuberculosis: old and new vaccines

Paediatric Respiratory Reviews

Volumn 8, Issue 2, 2007, Pages 148-154

  Hussey, Gregory ^a   Hawkridge, Tony ^a   Hanekom, Willem ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

BCG; HIV; TB vaccines; tuberculosis

Indexed keywords

AERAS 402 VACCINE; BACTERIAL VACCINE; BCG VACCINE; GAMMA INTERFERON; MTB72F VACCINE; MVA85A VACCINE; RBCG30 VACCINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EPIDEMIC; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LUNG DISEASE; MENINGITIS; META ANALYSIS; MILIARY TUBERCULOSIS; MULTIDRUG RESISTANCE; MYALGIA; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; CHILD; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 34249986446     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2007.04.009     Document Type: Review

References (66)

1. Trouiller P., Olliaro P., Torreele E., Orbinski J., Laing R., and Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (2002) 2188-2194
2. Dye C. The global epidemiology of tuberculosis. Lancet 267 (2006) 938-940
3. World Health Organisation. WHO Declares TB an Emergency in Africa. http://www.who.int/mediacentre/news/releases/2005/africa_emergency/en/index.html (accessed April 2, 2007).
4. Fine PA, Carneiro IAM, Milstein J, Clements CJ. Issues Relating to the Use of BCG in Immunization Programmes: A Discussion Document. WHO/V&B/99.23. Geneva: WHO, 1999.
5. National Institutes of Health. Tuberculosis Vaccines: State of the Science. http://www.niaid.nih.gov/dmid/tuberculosis/tbvaccine.htm (accessed April 4, 2007).
6. Behr M.A., Wilson M.A., Gill W.P., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1284 (1999) 1520-1523
7. World Health Organisation. BCG - the Current Vaccine for Tuberculosis. http://www.who.int/vaccine_research/diseases/tb/vaccine_development/bcg/en/ (accessed April 4, 2007).
8. Colditz G.A., Brewer T.F., Berkey C.S., et al. Efficacy of BCG vaccine in the prevention of tuberculosis - meta-analysis of the published literature. JAMA 271 (1994) 698-702
9. Rodrigues L.C., Diwan V.K., and Wheeler L.G. Protective effect of BCG against tuberculous meningitis and military tuberculosis: a meta-analysis. Int J Epidemiol 22 (1993) 1154-1158
10. Trunz B., Fine P., and Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367 (2006) 1173-1180
11. Kristensen I., Aaby P., and Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. Br Med J 321 (2000) 1-7
12. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
13. Black G.F., Dockrell H.M., Crampin A.C., et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in Northern Malawi. J Infect Dis 184 (2001) 322-329
14. Brandt L., Cunha J.F., Olsen A.W., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70 (2002) 672-678
15. Hussey G.D., Goddard E., Watkins M., et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 105 (2002) 314-324
16. World Health Organisation. BCG vaccine. Wkly Epidemiol Rep 79 (2004) 25-40
17. Hesseling A.C., Marais B.J., Gie R.P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25 (2007) 14-18
18. World Health Organization. Global Advisory Committee on Vaccine Safety, 29-30th November 2006. WER 2007; 82: 2-8.
19. Von Reyn C.F., and Vuoya J.M. New vaccines for the prevention of tuberculosis. Clin Infect Dis 35 (2002) 465-474
20. Ginsberg A. What's new in tuberculosis vaccines. Bull WHO 80 (2002) 483-488
21. Hoft D.F., Worku S., Kampmann B., et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 186 (2002) 1448-1457
22. Marchant A., Goetghebuer T., Ota M.O., et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 163 (1999) 2249-2255
23. Hanekom WA, The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 2005; 1062: 69-78.
24. Davids V., Hanekom W.A., Mansoor N., et al. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 193 (2006) 531-536
25. Weir R.E., Black G.F., Nazareth B., et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 146 (2006) 390-399
26. Smith S.M., Brookes R., Klein M.R., et al. Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A. J Immunol 165 (2000) 7088-7095
27. Murray R.A., Mansoor N., Harbacheuski R., et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol 177 (2006) 5647-5651
28. Hanekom WA. Unpublished observations, 2006.
29. Orme I.M. Mouse and guinea pig models for testing new tuberculosis vaccines. Tuberculosis (Edinb) 85 (2005) 13-17
30. Flynn J.L. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8 (2006) 1179-1188
31. Flynn J.L. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84 (2004) 93-101
32. Kaufmann S.H. New issues in tuberculosis. Ann Rheum Dis 63 Suppl 2 (2004) ii50-ii56
33. Freidag B.L., Melton G.B., Collins F., et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun 68 (2000) 2948-2953
34. Agger E.M., Rosenkrans I., Olsen A.W., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 (2006) 5452-5460
35. Hovav A.H., Mullerad J., Davidovitch L., et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 71 (2003) 3146-3154
36. Hope J.C., Thom M.L., Villareal-Ramos B., et al. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin Exp Immunol 139 (2005) 48-56
37. Bennekov T., Dietrich J., Rosenkrands I., et al. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol 36 (2006) 3346-3355
38. Buddle B.M., Wedlock D.N., Parlane W.A., et al. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immun 71 (2003) 6411-6419
39. Hoft DF. Personal communication, 2006.
40. McShane H., Pathan A.A., Sander C.R., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244 erratum in Nat Med 2004; 10: 1397
41. Kaufmann S.H.E., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Med Rev 11 (2005) S33
42. Skeiky Y., and Sadoff J. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
43. Koch R. Fortstzung über ein Heilmittel gegen Tuberculose. Dtsch Med Wochenschr 17 (1891) 101-102
44. Taylor J.L., Turner O.C., Basaraba R.J., Belisle J.T., Huygen K., and Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 (2003) 2192-2198
45. Huygen K., Content J., Denis O., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 (1996) 893-898
46. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 99 (1974) 2386-2392
47. Mahnel H., and Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl Munch Tierarztl Wochenschr 107 (1994) 253-256
48. Cosma A., Nagaraj R., Buhler S., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
49. Harrer E., Bauerle M., Ferstl B., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10 (2005) 285-300
50. McShane H. Personal communication, 2007.
51. Hawkridge A.J. Phase one trial of modified vaccinia Ankara tuberculosis vaccine in adults in a high TB prevalence setting in South Africa Tuberculosis. Vaccines for the World Conference, Vienna, April 19-21 (2006)
52. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 (2003) 1672-1679
53. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA. 97 (2000) 13853-13858
54. Hoft DF. Results of the 1st phase I trial of a recombinant BCG TB vaccine (rBCG30). Presented at US-Japan Cooperative Medical Science Program; 40th Tuberculosis and Leprosy Research Conference, Seattle, Washington, 2005.
55. Aeras Global Tuberculosis Vaccine Foundation. Clinical Trial of a New TB Vaccine in the U.S. Begins. February 17, 2004. http://www.aeras.org/news/releases/02172004.html.
56. Skeiky Y.A., Alderson M.R., Ovendale P.J., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
57. Ofori O. Personal communication, 2007.
58. Skjot R.L., Oettinger T., Rosenkrands I., et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68 (2000) 214-220
59. Skjot R.L., Brock I., Arend S.M., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the ESAT-6 gene family. Infect Immun 70 (2002) 5446-5453
60. Vogels R., Zuijdgeest D., van Rijnsoever R., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003) 8263-8271
61. Kostense S., Koudstaal W., Sprangers M., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 (2004) 1213-1216
62. Cole S.T., Brosch R., Parkhill J., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
63. Stop TB Partnership and World Health Organisation. Global Plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva: World Health Organization.
64. Kaufmann S.H.E. Is the development of a new tuberculosis vaccine possible?. Nature Med 6 (2000) 955-960
65. Comstock G.W. Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 15 (1994) 247-276
66. Kaufmann S.H.E., and Parida S. Changing funding patterns in tuberculosis. Nat Med 13 (2007) 299-303